Baird Medical Investment Holdings Limited (NASDAQ:BDMD) Stock Short Interest Report for October

Baird Medical Investment Holdings Limited (NASDAQ:BDMD) saw a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 217,561 shares, a growth of 858.6% from the October 15th total of 22,695 shares. Based on an average daily volume of 1,165,388 shares, the short-interest ratio is currently 0.2 days. Currently, 2.4% of the shares of the stock are short sold.

Baird Medical Investment Stock Performance

Shares of Baird Medical Investment stock remained flat at $0.10 during trading on Thursday. The stock had a trading volume of 92,478,901 shares, compared to its average volume of 5,133,173. The company has a fifty day simple moving average of $0.65 and a 200-day simple moving average of $1.29. Baird Medical Investment has a 12 month low of $0.07 and a 12 month high of $3.70.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Baird Medical Investment from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Baird Medical Investment stock. Citadel Advisors LLC purchased a new position in shares of Baird Medical Investment Holdings Limited (NASDAQ:BDMD) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 54,895 shares of the company’s stock, valued at approximately $63,000. Citadel Advisors LLC owned 0.13% of Baird Medical Investment as of its most recent filing with the SEC. Hedge funds and other institutional investors own 19.78% of the company’s stock.

Baird Medical Investment Company Profile

Baird Medical Investment Holdings Limited is a medical device company focused on minimally invasive tumor treatment technologies. Through its operating subsidiaries, the company develops, manufactures and markets microwave ablation systems designed to destroy targeted tissue using heat generated by microwave energy. Its product portfolio includes microwave ablation generators, disposable ablation needles and related accessories. The systems are used primarily in the treatment of thyroid nodules and other solid tumors, with applications that may include liver, breast and other soft-tissue conditions.